Pharma exports seen at 10-11% in next fiscal: CRISIL

Pharmaceutical exports (API and formulations) are expected to sustain 10-11% growth in the next fiscal. Strong US sales are likely to offset increased regulatory scrutiny and currency headwinds in markets such as Europe, and Latin America.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead master your money SME Special
moneycontrol.com

Home » News » Economy

Feb 26, 2016, 07.38 PM | Source: Moneycontrol.com

Pharma exports seen at 10-11% in next fiscal: CRISIL

Pharmaceutical exports (API and formulations) are expected to sustain 10-11% growth in the next fiscal. Strong US sales are likely to offset increased regulatory scrutiny and currency headwinds in markets such as Europe, and Latin America.

Like this story, share it with millions of investors on M3

Pharma exports seen at 10-11% in next fiscal: CRISIL

Pharmaceutical exports (API and formulations) are expected to sustain 10-11% growth in the next fiscal. Strong US sales are likely to offset increased regulatory scrutiny and currency headwinds in markets such as Europe, and Latin America.

Post Your Comments

Share Cancel

Below is snapview of the state of capital goods industry by CRISIL Research

Healthy growth foreseen

▪ Domestic formulation sales are expected to grow by 13-14% in the next fiscal, aided by strong growth in chronic care therapies and minimal impact from expected pricing interventions

▪ Pharmaceutical exports (API and formulations) are expected to sustain 10-11% growth in the next fiscal. Strong US sales are likely to offset increased regulatory scrutiny and currency headwinds in markets such as Europe, and Latin America.

Margin to remain range-bound

▪ Operating margin of formulation companies is likely to be range-bound (large companies 24-25% and mid-sized 18-20%) next fiscal. Margin expansion, due to improved export realisations, will be limited by a rise in research and development (R&D) and compliance costs.

▪ Margins of bulk drug players are also likely to remain range-bound (17-19%) next fiscal largely on account of pricing pressures, which will limit the benefit of improved volumes.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Pharma exports seen at 10-11% in next fiscal: CRISIL

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login